• Kripto Paralar
  • Tahmin Piyasaları
  • Haberler
  • Ajansal İşlem
  • Yazılar
  • Ligler

Kripto Paraları Ara

Trend Kripto Paralar

CoinRithm

Şirket

Tüzel Kişilik
Bees-x Limited
Şirket Numarası
13308136
Kuruluş Yeri
England and Wales
Kayıtlı Ofis
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm, Bees-x Limited tarafından işletilen bir bilgi ve araştırma hizmetidir. Düzenlenmiş faaliyetleri yürütmek üzere Financial Conduct Authority (FCA) tarafından yetkilendirilmemiştir ve bu sitedeki hiçbir içerik finansal tavsiye değildir.

Keşfet

Kripto ParalarTahmin PiyasalarıHaberlerYazılarAgent ArenaLigler

Özellikler

Kontrol PaneliTicaret SimülasyonuAjansal İşlemPortföyİzleme ListesiAyarlar

Şirket

HakkımızdaMetodolojiKullanım ŞartlarıGizlilik PolitikasıÇerez PolitikasıFeragatname

Destek

Destekle İletişimSSSGeliştirici kitiMCP belgeleri

Sosyal Medya

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tüm hakları saklıdır.
Google Play'de edininApp Store'dan İndirin
  • Ana Sayfa
  • PiyasalarTahmin Piyasaları
  • Haberler
  • Kontrol Paneli
  1. Tahmin Piyasaları
  2. Health & Medicine
  3. FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?
FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?

FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?

2.0% (24s)Health & MedicineOne-Off7g
PolymarketPolymarketKullanılabilirliği kontrol etKYC yok%2 ücret
Güncel ima edilen olasılık
Evet
Evet 83%+0.0%
Piyasa kalitesi

49 / 100

Düşük kalite
24s Hacim

₺636,2

Likidite

₺19 B

Düşük likidite
Alis / Satis

82.0% / 84.0%

Spread

2.4%

Dar spread
Piyasa verileri

4 dakika önce guncellendi

4 Haz 26 19:3519 Haz 26 0:00

Trendler

Sonuç24sOlasılık

Seçilen sonuç

Yes83%

Kurallar

As of market creation, the FDA's expected decision date for the specified application is June 19, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Merck's Welireg + Keytruda or Keytruda Qlex as a treatment for adjuvant treatment of clear cell renal cell carcinoma following nephrectomy by July 3, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

İlgili Piyasalar

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

₺7,9 Mn
Evet: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

₺886,8 B
Evet: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

₺468,1 B
Evet: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

₺67 B
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

₺24,7 B
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

₺7,3 B
2025: 0%Manifold MarketsMANIFOLD MARKETS

Bu konularda aktif

BitcoinBTC$62,755.45+1.95%EthereumETH$1,656.29+1.26%SolanaSOL$65.10+1.62%DogecoinDOGE$0.0849+1.34%XRPXRP$1.12+0.46%BNBBNB$599.48+2.22%

İlgili Haberler

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Kurallar

As of market creation, the FDA's expected decision date for the specified application is June 19, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Merck's Welireg + Keytruda or Keytruda Qlex as a treatment for adjuvant treatment of clear cell renal cell carcinoma following nephrectomy by July 3, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs